Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Total Liabilities (2019 - 2026)

BioScience Health Innovations has reported Total Liabilities over the past 8 years, most recently at $645749.0 for Q1 2026.

  • Quarterly Total Liabilities rose 385.81% to $645749.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $645749.0 through Mar 2026, up 385.81% year-over-year, with the annual reading at $229851.0 for FY2025, 496.27% up from the prior year.
  • Total Liabilities was $645749.0 for Q1 2026 at BioScience Health Innovations, up from $229851.0 in the prior quarter.
  • Over five years, Total Liabilities peaked at $645749.0 in Q1 2026 and troughed at $1860.0 in Q3 2022.
  • The 5-year median for Total Liabilities is $86399.0 (2023), against an average of $135762.2.
  • Year-over-year, Total Liabilities tumbled 90.26% in 2022 and then surged 1277.58% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $2867.0 in 2022, then surged by 3393.13% to $100148.0 in 2023, then plummeted by 61.51% to $38548.0 in 2024, then skyrocketed by 496.27% to $229851.0 in 2025, then surged by 180.94% to $645749.0 in 2026.
  • Per Business Quant, the three most recent readings for BHIC's Total Liabilities are $645749.0 (Q1 2026), $229851.0 (Q4 2025), and $356140.0 (Q3 2025).